Neisseria meningitidis serogroup A vaccines: An overview

Expert Review of Vaccines

Volumn 2, Issue 4, 2003, Pages 571-582

  Vergnano, Stefania ^b   Heath, Paul ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Conjugate vaccine; Epidemiology; Mass vaccination; Meningococcal vaccines; Neisseria meningitidis; Polysaccharide vaccine

Indexed keywords

ACW 135; DIPHTHERIA TOXIN; DIPHTHERIA TOXOID; INACTIVATED VACCINE; MENINGOCOCCUS A CONJUGATE VACCINE; MENINGOCOCCUS C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG; W 135;

AFRICA; BACTERIAL TRANSMISSION; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; EPIDEMIC; EPIDEMIC MENINGITIS; EPIDEMIOLOGICAL DATA; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VACCINATION; VACCINATION REACTION;

AFRICA; HUMANS; MASS IMMUNIZATION; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; POLYSACCHARIDES, BACTERIAL; VACCINATION; VACCINES, CONJUGATE;

EID: 0043235638     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.4.571     Document Type: Review

References (60)

1. Meningococcal disease, Great Lakes area (Burundi, Rwanda, United Republic of Tanzania) - update. Wkly Epidemiol. Rec. 77, 317 (2002).
2. Zhu P, van der Ende A, Falush D et al. Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis. Proc. Natl Acad. Sci. USA 98, 5234-5239 (2001).
3. Jodar L, Feavers IM, Salisbury D, Granoff DM. Development of vaccines against meningococcal disease. Lancet 359, 1499-1508 (2002).
4. Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect. Dis. Clin. N. Am. 15, 155-169 (2001).
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129, 1307-1326 (1969). Classic paper describing immunity to meningococci.
6. Rosestein N, Perkins B, Stephens D, Popovic T, Highes J. Medical progress: meningococcal disease. N. Engl. J. Med 344, 1378-1388 (2001).
7. Hart CA, Cuevas LE. Meningococcal disease in Africa. Ann. Trop. Med. Parasitol. 91, 777-785 (1997).
8. Veeken H, Ritmeijer K, Hausman B. Priority during a meningitis epidemic: vaccination or treatment? Bull. World Health Organ. 76, 135-141 (1998).
9. Frasch C. Meningococcal Vaccines: past, present and future. In: Meningococal disease. Wiley, Chicester, UK, 246-283 (1995).
10. Molesworth AM, Thomson MC, Connor SJ et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R. Soc. Trop. Med. Hyg. 96, 242-249 (2002).
11. Memish ZA, Alrajhi AA. Meningococcal disease. Saudi Med. J. 23, 259-264 (2002).
12. Kwara A, Adegbola RA, Corrah PT et al. Meningitis caused by a serogroup W135 done of the ET-37 complex of Neisseria meningitidis in West Africa. Trop. Med. Int. Health, 3, 742-746 (1998).
13. MacLennan JM, Urwin R, Obaro S, Griffiths D, Greenwood B, Maiden MC. Carriage of serogroup W-135, ET-37 meningococci in the Gambia: implications for immunisation policy? Lancet 356, 1078 (2000).
14. Lepow ML, Perkins BA, Hughes PA, Poolman JT. Meningococcal vaccines. In: Vaccines 3rd Edition. Plotkin SA, Orenstein WA (Eds). WB Saunders, PA, USA, 711-724 (1999).
15. Ceesay SJ, Allen SJ, Menon A et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J. Infect. Dis. 167, 1212-1216 (1993).
16. Reingold AL, Broome CV, Hightower AW et al. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2, 114-118 (1985).
17. MacDonald NE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated versus plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 280, 1685-1689 (1998).
18. MacLennan J, Obaro S, Deeks J et al. Immune response to revaccination with meningococcal A and C polysaccharides in Gambian children following repeated immunisation during early childhood. Vaccine 17, 3086-3093 (1999).
19. Williamson WA, Greenwood BM. Impairment of the immune response to vaccination after acute malaria. Lancet 1, 1328-1329 (1978).
20. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst. Rev. 3, CD001093 (2001). Systematic review of studies of polysaccharide vaccines for preventing meningococcal A disease.
21. Kaninda AV, Belanger F, Lewis R et al. Effectiveness of incidence thresholds for detection and control of meningococcal meningitis epidemics in northern Togo. Int. J. Epidemiol. 29, 933-940 (2000).
22. Perkins BA. Prospects for prevention of meningococcal meningitis. Lancet 358, 255-256 (2001).
23. Lewis R, Nathan N, Diarra L, Belanger F, Paquet C. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 358, 287-293 (2001).
24. Detecting meningococcal meningitis epidemics in highly-endemic African countries. Wkly Epidemiol. Rec. 75, 306-309 (2000).
25. Woods CW, Armstrong G, Sackey SO et al. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 355, 30-33 (2000).
26. Miller MA, Wenger J, Rosenstein N, Perkins B. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr. Infect. Dis. J. 18, 1051-1059 (1999). An analysis of different prevention strategies.
27. de Chabalier F, Chippaux JP, Massougbodji A. Meningococcal immunisation in Ghana. Lancet 355, 2252-2253 (2000).
28. McDamien D, Boelaert M, Van Damme W, Van der Stuyft P. Meningococcal immunisation in Ghana. Lancet 355, 2252-2253 (2000).
29. Campagne G, Schuchat A, Djibo S, Ousseini A, Cisse L, Chippaux JP. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Bull. World Health Organ. 77, 499-508 (1999).
30. Hassan J, Massougbodji A, Chippaux JP, Massit B, Josse R. Meningococcal immunisation and protection from epidemics. Lancet 352, 407-408 (1998).
31. Chippaux JP, Campagne G, Djibo S, Cisse L, Hassane A, Kanta I. Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt. Ann. Trop. Med. Parasitol. 93, 505-510 (1999).
32. Bovier PA, Wyss K, Au HJ. A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. Soc. Sci. Med 48, 1205-1220 (1999).
33. Goldblatt D. Recent developments in bacterial conjugate vaccines. J. Med Microbiol. 47, 563-567 (1998).
34. Rappuoli R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 19, 2319-2322 (2001).
35. International co-ordinating group on vaccine provision for epidemic meningitis control. Report of the 7th meeting. WHO, Geneva, Switzerland (2001).
36. Jodar L, LaForce F, Ceccarini C, Aguado T, Granoff D. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 361(9372), 1902-1904 (2003). Exciting developments for an affordable conjugate vaccine for Africa.
37. Anderson EL, Bowers T, Mink CM et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect. Immun. 62, 3391-3395 (1994).
38. Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA 275, 1499-1503 (1996).
39. Campagne G, Garba A, Fabre P et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A + C diphtheria conjugate vaccine in infants from Niger. Pediatr. Infect. Dis. J. 19, 144-150 (2000).
40. Twumasi PA, Jr., Kumah S, Leach A et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 71, 632-638 (1995).
41. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174, 1360-1363 (1996).
42. Leach A, Twumasi PA, Kumah S et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175, 200-204 (1997).
43. Borrow R, Fox AJ, Richmond PC et al. Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine. Epidemiol. Infect. 124, 427-432 (2000).
44. MacLennan J, Obaro S, Deeks J et al. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy. J. Infect. Dis. 183, 97-104 (2001).
45. Joseph H, Miller E, Dawson M, Andrews N, Feavers I, Borrow R. Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J. Infect. Dis. 184, 661-662 (2000).
46. Rennels M, King J Jr, Ryall R et al. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr. Infect. Dis. J. 21, 978-979 (2002).
47. Lakshman R, Burkinshaw R, Choo S, Finn A. Prior meningococcal A/C polysaccharide vaccine does not reduce immune responses to conjugate vaccine inyoung adults. Vaccine 20, 3778-3782 (2002).
48. Takala AK, Eskola J, Leinonen M et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine. J. Infect. Dis. 164, 982-986 (1991).
49. Nurkka A, MacLennan J, Jantti V, Obaro S, Greenwood B, Kayhty H. Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children. Vaccine 19, 547-556 (2001).
50. Zhang Q, Lakshman R, Burkinshaw R et al. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom. Infect. Immun. 69, 4337-4341 (2001).
51. Perkins BA. New opportunities for prevention of meningococcal disease. JAMA 283, 2842-2843 (2000).
52. Grothaus MC, Srivastava N, Smithson SL et al. Selection of an immunogenic peptide mimic of the capsular polysaccharide of Neisseria meningitidis serogroup A using a peptide display library. Vaccine 18, 1253-1263 (2000).
53. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N. Engl. J. Med. 344, 1378-1388 (2001).
54. Bethell D, Pollard A. Meningococcal vaccines. Expert Rev. Vaccines 1, 75-84 (2002).
55. Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR, Martin D. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect. Immun. 67, 4955-4959 (1999).
56. Plested JS, Makepeace K, Jennings MP et al. Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis. Infect. Immun. 67, 5417-5426 (1999).
57. Robbins JB, Schneerson R, Gotschlich EC. A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr. Infect. Dis. J. 19(10), 945-953 (2000). A summary of the arguments for routine vaccination with polysaccharide vaccine.
58. WHO: World Health Organization who.int/emc/diseases/meningitis/index.html
59. WHO: 'Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition' 1998 www.who.int/emc-documents/meningitis/docs/whoemcbac.983.pdf WHO guidelines for epidemics.
60. GAVI Global alliance for vaccines and Immunisation www.vaccinealliance.org/home/index.php